Curis to Present Updated Data from the TakeAim Leukemia Study

Curis, Inc. (NASDAQ: CRIS) will present updated data from the TakeAim Leukemia study on May 14, 2024.

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) will present updated data from the TakeAim Leukemia study on May 14, 2024. The company focuses on emavusertib (CA-4948), an IRAK4 inhibitor. A conference call will follow the presentation.

Argus Session date unavailable

-4.78% session move Open Argus

Details

News Market Reaction – CRIS

The recorded move for CRIS in the trading session of this news was -4.78%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET.

To access the live conference call, please dial 800-836-8184 from the United States or 646-357-8785 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-updated-data-from-the-takeaim-leukemia-study-302141930.html

SOURCE Curis, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Curis present updated data from the TakeAim Leukemia study?

Curis will present updated data on May 14, 2024.

What is Curis focused on?

Curis focuses on emavusertib (CA-4948), an IRAK4 inhibitor.

What is the stock symbol for Curis?

The stock symbol for Curis is CRIS.

Where can I access the conference call?

The conference call can be accessed on the Curis website in the 'Investors' section.

How can I participate in the conference call?

To participate in the conference call, dial 800-836-8184 from the United States or 646-357-8785 from other locations shortly before 4:30 p.m. ET.